Citigroup’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-657,223
| Closed | -$26.4M | – | 5709 |
|
|
2026
Q1 | $26.4M | Buy |
657,223
+35,065
| +6% | +$756K | 0.01% | 929 |
|
|
2025
Q4 | $15.6M | Buy |
622,158
+177,186
| +40% | +$4.16M | 0.01% | 1243 |
|
|
2025
Q3 | $10.1M | Buy |
444,972
+306,521
| +221% | +$7.15M | ﹤0.01% | 1489 |
|
|
2025
Q2 | $2.4M | Sell |
138,451
-278,168
| -67% | -$5.15M | ﹤0.01% | 2480 |
|
|
2025
Q1 | $9.11M | Buy |
416,619
+224,458
| +117% | +$6.2M | ﹤0.01% | 1430 |
|
|
2024
Q4 | $6.13M | Buy |
192,161
+179,999
| +1,480% | +$5.41M | ﹤0.01% | 1760 |
|
|
2024
Q3 | $351K | Sell |
12,162
-30,507
| -71% | -$1.13M | ﹤0.01% | 3968 |
|
|
2024
Q2 | $1.64M | Sell |
42,669
-219,039
| -84% | -$9.92M | ﹤0.01% | 2516 |
|
|
2024
Q1 | $15.4M | Buy |
261,708
+175,167
| +202% | +$11.2M | 0.01% | 1018 |
|
|
2023
Q4 | $5.18M | Sell |
86,541
-30,355
| -26% | -$1.54M | ﹤0.01% | 1569 |
|
|
2023
Q3 | $4.45M | Buy |
116,896
+36,911
| +46% | +$1.62M | ﹤0.01% | 1499 |
|
|
2023
Q2 | $7.29M | Sell |
79,985
-43,422
| -35% | -$3.75M | ﹤0.01% | 1283 |
|
|
2023
Q1 | $8.14M | Buy |
123,407
+41,307
| +50% | +$2.38M | 0.01% | 1254 |
|
|
2022
Q4 | $4.25M | Sell |
82,100
-15,732
| -16% | -$834K | ﹤0.01% | 1552 |
|
|
2022
Q3 | $6.68M | Sell |
97,832
-4,128
| -4% | -$244K | ﹤0.01% | 1377 |
|
|
2022
Q2 | $4.61M | Buy |
101,960
+75,276
| +282% | +$3.43M | ﹤0.01% | 1585 |
|
|
2022
Q1 | $1.36M | Sell |
26,684
-93,004
| -78% | -$4.11M | ﹤0.01% | 2680 |
|
|
2021
Q4 | $5.66M | Buy |
119,688
+49,396
| +70% | +$1.94M | ﹤0.01% | 1737 |
|
|
2021
Q3 | $2.32M | Sell |
70,292
-22,436
| -24% | -$1.26M | ﹤0.01% | 2422 |
|
|
2021
Q2 | $5.86M | Sell |
92,728
-5,346
| -5% | -$276K | ﹤0.01% | 1777 |
|
|
2021
Q1 | $4.21M | Buy |
98,074
+2,888
| +3% | +$137K | ﹤0.01% | 1904 |
|
|
2020
Q4 | $5.45M | Buy |
95,186
+85,979
| +934% | +$3.64M | ﹤0.01% | 2018 |
|
|
2020
Q3 | $278K | Sell |
9,207
-58,578
| -86% | -$1.75M | ﹤0.01% | 4345 |
|
|
2020
Q2 | $2.21M | Buy |
67,785
+15,336
| +29% | +$493K | ﹤0.01% | 2700 |
|
|
2020
Q1 | $1.41M | Sell |
52,449
-28,587
| -35% | -$1.01M | ﹤0.01% | 2829 |
|
|
2019
Q4 | $2.48M | Buy |
81,036
+45,113
| +126% | +$1.25M | ﹤0.01% | 2762 |
|
|
2019
Q3 | $865K | Sell |
35,923
-11,099
| -24% | -$305K | ﹤0.01% | 3804 |
|
|
2019
Q2 | $1.19M | Buy |
47,022
+23,547
| +100% | +$479K | ﹤0.01% | 3420 |
|
|
2019
Q1 | $458K | Sell |
23,475
-27,438
| -54% | -$432K | ﹤0.01% | 4282 |
|
|
2018
Q4 | $672K | Buy |
50,913
+3,386
| +7% | +$52K | ﹤0.01% | 3813 |
|
|
2018
Q3 | $845K | Buy |
47,527
+20,301
| +75% | +$375K | ﹤0.01% | 3684 |
|
|
2018
Q2 | $599K | Buy |
27,226
+27,206
| +136,030% | +$625K | ﹤0.01% | 3896 |
|
|
2018
Q1 | $0 | Sell |
20
-1,200
| -98% | -$23.6K | ﹤0.01% | 7523 |
|
|
2017
Q4 | $26K | Buy |
+1,220
| New | +$18K | ﹤0.01% | 6586 |
|
Other funds holding APLS
Citigroup's APLS Position: Q2 2026 in Review
Citigroup sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 657,223 shares — an estimated $26.4M sold.
Citigroup first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $26.4M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Citigroup reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citigroup sold 657,223 Apellis Pharmaceuticals shares in Q2 2026, an estimated $26.4M.
- Citigroup first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Citigroup's Apellis Pharmaceuticals position peaked at $26.4M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.